• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Ionis to present at upcoming investor conferences

    3/31/25 7:05:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IONS alert in real time by email

    Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will participate in fireside chats at the following investor conferences:

    • 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025
    • Bank of America 2025 Health Care Conference on Wednesday, May 14, 2025
    • 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025

    A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

    About Ionis Pharmaceuticals

    For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250331048554/en/

    Ionis Pharmaceuticals Investor Contact:

    D. Wade Walke, Ph.D. – [email protected] – 760-603-2331



    Ionis Pharmaceuticals Media Contact:

    Hayley Soffer – [email protected] – 760-603-4679

    Get the next $IONS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IONS

    DatePrice TargetRatingAnalyst
    4/7/2025$45.00Buy
    H.C. Wainwright
    3/31/2025$39.00Neutral
    Redburn Atlantic
    8/2/2024$67.00 → $60.00Outperform → Market Perform
    BMO Capital Markets
    7/24/2024$53.00 → $62.00Market Perform → Outperform
    Leerink Partners
    7/16/2024$29.00 → $75.00Buy
    Jefferies
    6/14/2024$44.00Underperform → Mkt Perform
    Bernstein
    4/10/2024$58.00Peer Perform → Outperform
    Wolfe Research
    1/2/2024$52.00 → $62.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $IONS
    SEC Filings

    See more
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      6/12/25 9:00:44 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      6/10/25 6:02:16 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      5/19/25 7:18:21 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Ionis Pharma with a new price target

      H.C. Wainwright initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $45.00

      4/7/25 8:43:57 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redburn Atlantic initiated coverage on Ionis Pharma with a new price target

      Redburn Atlantic initiated coverage of Ionis Pharma with a rating of Neutral and set a new price target of $39.00

      3/31/25 8:13:04 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharma downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Ionis Pharma from Outperform to Market Perform and set a new price target of $60.00 from $67.00 previously

      8/2/24 7:32:04 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

      Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role. "Richard has made tremendous contributions to Ionis over his 30-year tenure during which he spearheaded dozens of development programs and brought six innovative medicines through regulatory approvals, including TRYNGOLZA, our first independent commercial medicine. We thank him for his leadership and unwavering dedication to patients in need," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "Holl

      6/12/25 9:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

      - Completion of enrollment anticipated in 2026 - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate the efficacy and safety of ION582, an investigational medicine for the treatment of people living with Angelman syndrome (AS), a serious and rare neurodevelopmental disorder that leads to significant physical and cognitive impairments. "Dosing the first person with Angelman syndrome in our pivotal REVEAL study marks an important milestone for this underserved community, who currently have no approved disease modifying treatments," said Holly Kordasiewicz, Ph.D., senior vice p

      6/11/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

      – Olezarsen met the primary endpoint with a statistically significant mean reduction in triglycerides versus placebo at 80 mg and 50 mg doses – – Olezarsen met all key secondary endpoints – – Olezarsen demonstrated a favorable safety and tolerability profile – – Nearly 1,500-person Phase 3 study supports the exposure database for olezarsen – – Data from pivotal Phase 3 CORE and CORE2 studies of olezarsen in severe hypertriglyceridemia (sHTG) expected in Q3 2025 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced positive topline results from the Essence study of olezarsen in people with moderate hypertriglyceridemia (fasting triglycerides ≥150 mg/dL to <500 mg/dL) with or at risk f

      5/19/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care